CoChat

Society of Toxicologic Pathology Digital Pathology and Image Analysis Special Interest Group Article*: Opinion on the Application of Artificial Intelligence and Machine Learning to Digital Toxicologic Pathology

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Abstract

Toxicologic pathology is transitioning from analog to digital methods. This transition seems inevitable due to a host of ongoing social and medical technological forces. Of these, artificial intelligence (AI) and in particular machine learning (ML) are globally disruptive, rapidly growing sectors of technology whose impact on the long-established field of histopathology is quickly being realized. The development of increasing numbers of algorithms, peering ever deeper into the histopathological space, has demonstrated to the scientific community that AI pathology platforms are now poised to truly impact the future of precision and personalized medicine. However, as with all great technological advances, there are implementation and adoption challenges. This review aims to define common and relevant AI and ML terminology, describe data generation and interpretation, outline current and potential future business cases, discuss validation and regulatory hurdles, and most importantly, propose how overcoming the challenges of this burgeoning technology may shape toxicologic pathology for years to come, enabling pathologists to contribute even more effectively to answering scientific questions and solving global health issues. [Box: see text]

Overview

Integrity signals

Registry

Crossref · 10.1177/0192623319881401

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 21

  1. Ciresan D, Giusti A, Gambardella LM, Schmidhuber J. Deep Neural Networks Segment Neuronal Membranes In Electron Microscopy Images. Neural Information Processing Systems; 2012. https://papers.nips.cc/paper/4741-deep-neural-networks-segment-neuronal-membranes-in-electron-microscopy-images. Accessed October 2, 2019.
  2. Ciresan DC, 2013, Med Image Comput Comput Assist Interv, 16, 411
  3. Gibney E, Nature
  4. Mthembu L, Fifteenth Annual Symposium of the Pattern Recognition Association of South Africa, 2004
  5. Mthembu L, Marwala T. A note on the separability index. 2008. https://arxiv.org/abs/0812.1107. Accessed April 5, 2019. · arXiv
  6. Greene JR. Feature subset selection using Thornton’s separability index and its applicability to a number of sparse proximity-based classifiers. 2001. https://pdfs.semanticscholar.org/dacc/c51597af27682033bcdae55097d3faea7864.pdf. Accessed October 2, 2019.
  7. Fawcett T, 2004, Mach Learn, 1
  8. Chollet F, 2017, Deep Learning With Python
  9. van der Maaten LJP, 2008, J Mach Learn Res, 9, 2579
  10. McInnes L, 2018, ArXiv
  11. Ren J, 2015, IEEE Eng Med Bio, 2015, 3013
  12. Couture HD, 2018, NPJ Breast Cancer, 3, 4
  13. Schaumberg AJ, 2017, BioRxiv, 064279
  14. Rao S. MITOS-RCNN: a novel approach to mitotic figure detection in breast cancer histopathology images using region based convolutional neural networks. arXiv:1807.01788. https://arxiv.org/abs/1807.01788. Accessed October 2, 2019. · arXiv
  15. Komura D, 2018, biorxiv
  16. Otalora S, 2018, bioRxiv
  17. Pfizer. IBM and Pfizer to accelerate immuno-oncology research with Watson for drug discovery. 2016. https://www.pfizer.com/news/press-release/press-release-detail/ibm_and_pfizer_to_accelerate_immuno_oncology_research_with_watson_for_drug_discovery. Accessed August 5, 2019.
  18. Hipp JD, 2018, Proceedings of the American Association for Cancer Research Annual Meeting
  19. Solberg BL, 2012, Clin Lab Sci, 25
  20. Crowley RS, 2001, Proc AMIA Symp, 125
  21. Oxford. Essential Quotations: Roy Amara. Oxford, England: Oxford University Press. 2016. http://www.oxfordreference.com/view/10.1093/acref/9780191826719.001.0001/q-oro-ed4-00018679. Accessed April 05, 2019, 2019. · doi:10.1093/acref/9780191826719.001.0001/q-oro-ed4-00018679

Cited by

See all 85

Metadata

Authors
Turner, O. C., Aeffner, F., Bangari, D. S., High, W., Knight, B., Forest, T., Cossic, B., Himmel, L. E., Rudmann, D. G., Bawa, B., Muthuswamy, A., Aina, O. H., Edmondson, E. F., Saravanan, C., Brown, D. L., Sing, T., & Sebastian, M. M.
Affiliations
  • Novartis, Novartis Institutes for Biomedical Research, Preclinical Safety, East Hanover, NJ, USA
  • Amgen (United States) (US)
  • Sanofi, Global Discovery Pathology, Framingham, MA, USA
  • High Preclinical Pathology Consulting, Rochester, NY, USA
  • Boehringer Ingelheim (United States) (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • F. Hoffmann-La Roche AG (CH)
  • Vanderbilt University Medical Center (US)
  • Charles River Laboratories (United States) (US)
  • AbbVie (United States) (US)
  • Regeneron (United States) (US)
  • National Institutes of Health (US)
  • Novartis, Novartis Institutes for Biomedical Research, Preclinical Safety, Cambridge, MA, USA
  • Novartis (Switzerland) (CH)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Turner, Oliver C.
Venue
Toxicologic Pathology
Published
2019-10-23
Volume
48
Issue
2
Pages
277-294
ISSN
  • 0192-6233 (ISSN-L)
  • 1533-1601
OpenAlex
W2981553472
Cited by
64
References
148
Citations by year
2026: 5 · 2025: 14 · 2024: 6 · 2023: 8 · 2022: 5 · 2021: 16 · 2020: 10
FWCI
3.54
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Toxicologic Pathology (publishedVersion)
  • PubMed (publishedVersion)
  • The Novartis Repository (Novartis) (submittedVersion)
Topics
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
artificial intelligence, machine learning, digital pathology, histopathology, AI terminology, business case, validation, regulatory challenges, barriers to adoption, precision medicine
MeSH terms
Artificial Intelligence, Humans, Image Processing, Computer-Assisted, Pathology, Toxicology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.